Showing results (621-630 of 735) with videos related to
Sort By:
Pageof 74
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.Nature Communications|October 26, 2022
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancerFilipe Correia Martins, Dominique-Laurent Couturier, Ines de Santiago, et al.Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
The mutagenic forces shaping the genomic landscape of lung cancer in never smokersMarcos Díaz-Gay, Tongwu Zhang, Phuc H Hoang, et al.Nature Medicine|January 22, 2019
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesionsVitor H Teixeira, Christodoulos P Pipinikas, Adam Pennycuick, et al.Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced MelanomaGeorgina V Long, James Larkin, Dirk Schadendorf, et al.Contemporary Clinical Trials|September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma settingAngela Meade, Bhavna Oza, Eleni Frangou, et al.Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.Pageof 74